A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose, Multiple Dose, and Food Effect Trial of the Safety, Tolerability and Pharmacokinetics of Highly Purified Cannabidiol in Healthy Subjects

Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial

(2018) Elizabeth A Thiele et al.   LANCET

Randomized, dose-ranging safety trial of cannabidiol in Dravet syndrome

(2018) Orrin Devinsky et al.   NEUROLOGY

Effect of Cannabidiol on Drop Seizures in the Lennox–Gastaut Syndrome

(2018) Orrin Devinsky et al.   NEW ENGLAND JOURNAL OF MEDICINE

Interactions between cannabidiol and commonly used antiepileptic drugs

(2017) Tyler E. Gaston et al.   EPILEPSIA

The application of half-life in clinical decision making: Comparison of the pharmacokinetics of extended-release topiramate (USL255) and immediate-release topiramate

(2017) Barry E. Gidal et al.   EPILEPSY RESEARCH

Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome

(2017) Orrin Devinsky et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cannabinoids and Cytochrome P450 Interactions

(2016) Ondřej Zendulka et al.   CURRENT DRUG METABOLISM

Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex

(2016) Evan J. Hess et al.   EPILEPSIA

Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial

(2016) Orrin Devinsky et al.   LANCET NEUROLOGY

Are cannabidiol and Δ9-tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review

(2015) John M McPartland et al.   BRITISH JOURNAL OF PHARMACOLOGY

Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy

(2015) Alexandra L. Geffrey et al.   EPILEPSIA

Absorption-Enhancing Effects of Bile Salts

(2015) Eskandar Moghimipour et al.   MOLECULES

Molecular Targets of Cannabidiol in Neurological Disorders

(2015) Clementino Ibeas Bih et al.   Neurotherapeutics

Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review

(2013) Stephen M. Stout et al.   DRUG METABOLISM REVIEWS

Cannabinoid- and lysophosphatidylinositol-sensitive receptor GPR55 boosts neurotransmitter release at central synapses

(2013) S. Sylantyev et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes

(2011) Rongrong Jiang et al.   LIFE SCIENCES

Minireview: Recent Developments in the Physiology and Pathology of the Lysophosphatidylinositol-Sensitive Receptor GPR55

(2011) Christopher M. Henstridge et al.   MOLECULAR ENDOCRINOLOGY

Characterization of Human Hepatic and Extrahepatic UDP-Glucuronosyltransferase Enzymes Involved in the Metabolism of Classic Cannabinoids

(2009) A. Mazur et al.   DRUG METABOLISM AND DISPOSITION